Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Amgen Inc.: Company Profile and SWOT Analysis

VIEWS: 113 PAGES: 42

This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. ICD Research's "Amgen Inc.: Company Profile and SWOT Analysis" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

More Info
  • pg 1
									Amgen Inc.

_________________________________________________________________________________



Amgen Inc.                                                               Financial Snapshot

                                                                         Operating Performance
Fast Facts
                                One Amgen Center Drive, Thousand Oaks,   The company reported revenues of US$15,053.00
Headquarters Address
                                91320,United States of America           million during 2010, with a CAGR of 1.35% during
                                                                         2006–2010. Its revenue grew at an annual rate of
Telephone                       + 1 805 4471000
                                                                         2.81% over the previous fiscal year. In 2010, the
                                                                         company recorded an operating margin of 36.84%, as
Fax                             + 1 805 4471010                          against 37.60% in 2009.

Website                         www.amgen.com
                                                                         Revenue and Margins
Ticker Symbol, Stock Exchange   AMGN, NASDAQ

Number of Employees             17,100

Fiscal Year End                 December

Revenue (in US$ million)        15,053.00




SWOT Analysis

Strengths                       Weaknesses                               Return on Equity

Focus on R&D activities         High debt                                The company recorded a return on equity (ROE) of
                                                                         19.32% for 2010, as compared to its peers, Teva
                                                                         Pharmaceutical Industries Limited (Ticker: TEVA),
Global presence                                                          Chugai Pharmaceutical Co. Ltd (Ticker: 4519) and
                                                                         Nektar Therapeutics (Ticker: NKTR), which recorded
Wide product portfolio                                                   ROEs of 15.18%, 9.25% and -41.85% respectively.
                                                                         The company reported an operating margin of
                                                                         36.84% in 2010.
Opportunities                   Threats

Changing demographics           Competitive pressures                    Return on Equity


Geographic expansion            Counterfeit drugs

Product approvals               Pending legal proceedings

                                Tightening of the FDA’s regulatory
                                oversight




                                                                         Liquidity Position

                                                                         The company reported a current ratio of 3.52 in 2010,
                                                                         as compared to its peers, Teva Pharmaceutical
                                                                         Industries Limited, Chugai Pharmaceutical Co. Ltd
                                                                         and Nektar Therapeutics, which recorded current
                                                                         ratios of 1.24, 7.08 and 5.52 respectively. As of
                                                                         December 2010, the company recorded cash and
                                                                         short-term investments of worth US$17,422.00
                                                                         million, against US$2,488.00 million current debt. The
                                                                         company reported a debt to equity ratio of 0.56 in
                                                                         2010 as compared to its peers, Teva Pharmaceutical
                                                                         Industries Limited, Chugai Pharmaceutical Co. Ltd
                                                                         and Nektar Therapeutics, which recorded debt to
                                                                         equity ratios of 0.25, 0.00 and 2.56 respectively.




___________________________________________________________________________________________

Amgen Inc. - SWOT Profile                                                                                        Page 1
Amgen Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
2     Analysis of Key Performance Indicators ............................................................................................... 7
    2.1       Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................7
    2.2       Key Financial Performance Indicators .................................................................................................................10
      2.2.1       Revenue and Operating Profit .........................................................................................................................10
      2.2.2       Asset, Liabilities and Capex .............................................................................................................................11
      2.2.3       Net Debt vs. Gearing Ratio ..............................................................................................................................12
      2.2.4       Operational Efficiency ......................................................................................................................................13
      2.2.5       Solvency ..........................................................................................................................................................14
      2.2.6       Valuation ..........................................................................................................................................................15
    2.3       Competitive Benchmarking ..................................................................................................................................16
      2.3.1       Market Capitalization .......................................................................................................................................17
      2.3.2       Efficiency ..........................................................................................................................................................18
      2.3.3       Capital Expenditure ..........................................................................................................................................19
      2.3.4       Turnover – Inventory and Asset .......................................................................................................................20
3     Mergers & Acquisitions and Partnerships ........................................................................................... 21
    3.1       M&A and Partnerships Strategy ...........................................................................................................................21
4     Recent Developments ........................................................................................................................... 24
5     SWOT Analysis ...................................................................................................................................... 26
    5.1       SWOT Analysis - Overview ..................................................................................................................................26
    5.2       Strengths ..............................................................................................................................................................26
    5.3       Weaknesses .........................................................................................................................................................27
    5.4       Opportunities ...........................................................................................
								
To top